Resolving Serological Blood Group Discrepancy and Providing Transfusion Support in a Patient of Mixed Auto Immune Hemolytic Anemia: A Case Report
Journal Title: Haematology International Journal - Year 2018, Vol 2, Issue 1
Abstract
ABO grouping should include both forward and reverse grouping procedure, and results of two procedures should agree with each other. Mixed autoimmune hemolytic anemia (AIHA) is defined as presence of both warm and cold autoantibodies. Approximately 20% of AIHA are associated with cold-reactive antibodies. Warm autoantiboies are responsible for 48-70% of AIHA cases. About half of patients are termed idiopathic without any underlying causes. Secondary cases are associated with underlying diseases or with certain drugs. Diagnosis is based on detection of autoantibodies by monospecific Direct antiglobulin test (DAT) showing positive reaction on IgG and Complement C3d and presence of cold agglutinins. We report a case of mixed AIHA in 35 yr old lady who had severe anemia, blood group discrepancy, crossmatch incompatibility. We provided 2 units of Best matched blood (least incompatible) and she responded to corticosteroids. To our knowledge a careful communication between the transfusion services and clinicians can avoid unnecessary blood transfusions in such cases especially in clinically responding patients.
Authors and Affiliations
Dibyajyoti Sahoo
Keywords
Related Articles
- EP ID EP291056
- DOI -
- Views 95
- Downloads 0
Hypoarginaemia among Pre- School Children of African Descent with Plasmodium Falciparum Malaria
Malaria is a public health problem particularly in the tropical areas of the world affecting about 247 million people each year and often resulting in nearly a million deaths. It is the leading cause of under-five hospit...
Iatrogenic Cushing’s Syndrome with Secondary Adrenal Suppression Misdiagnosed as Protease Inhibitor-Induced Lipodystrophy in an HIV Positive Patient: Case Report
1.1. Background: Ritonavir is a commonly prescribed protease inhibitor (PI) which is used in low doses to boost levels of other protease inhibitors pharmacokinetically. It is a potent inhibitor of hepatic cytochrome P450...
Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
1.1. Background: A significant survival prolongation was recently reported by adding idelalisib to rituximab (IR) compared with rituximab (R) in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). No...
A Survey of Clinicians Practice Patterns in Anticoagulation Therapy & Prophylaxis in Nigeria
Introduction: Therapeutic and prophylactic anticoagulation is under-prescribed in Nigeria, Dismal practice patterns of anticoagulation, lack of hospital-based anticoagulation policy may be contributory Objective: The aim...
Long-lasting Responses to Immunomodulatory Drugs (IMIDs) in Combination with Dexamethasone in Multiple Myeloma; Identification of Exceptional Responders at any Treatment Line
1.1. Background: There is a growing interest in the study of patients that achieve exceptionally long-lasting remissions although suffering from incurable neoplastic disorders. This is the case for multiple myeloma (MM),...